Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Acute Myeloid Leukemia: Latest Advances in Diagnostics, Therapeutic Strategies and...
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Acute Myeloid Leukemia: Latest Advances in Diagnostics, Therapeutic Strategies and Clinical Management: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 20 April 2026 | Viewed by 1085

Special Issue Editor

Dr. Michael D. Diamantidis

E-Mail Website
Guest Editor
Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, 41221 Larissa, Greece
Interests: acute myeloid leukemia; myelodysplastic syndromes; myeloid malignancies; myeloproliferative neoplasms; hemoglobinopathies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce the 2nd Edition of this Special Issue following the great editorial success of the first Volume. You can view the papers of the first Edition through the link below:

https://www.mdpi.com/journal/jcm/special_issues/54AS713Q21

Amazing progress has been achieved in recent years regarding a better understanding of the genetic landscape of acute myeloid leukemia (AML) with the improvement of molecular diagnostics. This has led to novel classifications of the disease (ICC/ELN 2022 and WHO 2022), prognostic systems proposed by several scientific groups incorporating the genomic data of large series of AML patients with the contribution of bioinformatics, and most importantly, to the approval of novel agents for the treatment of AML. Nevertheless, there is an unmet need to solve novel challenges that have emerged.

The aim of this Special Issue is to reflect the core problems and the research regarding all aspects of AML: the genetic landscape of the disease, diagnostics, novel treatments, hematopoietic stem cell transplantation, and cellular therapies. The manuscripts submitted can be either original papers, reviews or even remarkable cases accompanied by a literature review. The basic biology of AML, novel advances regarding clonal evolution and leukemic stem cells, novel markers for diagnosis and prognosis of AML, comparison between ICC/ELN 2022 and WHO 2022 AML classifications, risk adapted therapy, novel targeted therapies, the role of measurable residual disease (MRD) in AML, current acute promyelocytic leukemia (APL) therapeutic strategies, immunotherapy of AML, CAR-T cells and AML are of interest for this Special Issue.

We thank you and we are looking forward to receiving your work.

Dr. Michael D. Diamantidis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ELN
  • ICC and WHO 2022 AML classifications
  • molecular AML diagnostics
  • AML biology
  • measurable residual disease (MRD)
  • novel targeted AML therapies
  • AML immunotherapies
  • hematopoietic stem cell transplantation (HSCT)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 2595 KB  
Article
Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry
by Volkan Karakus, Ibrahim Ethem Pinar, Utku Iltar, Emel Merve Yenihayat, Merve Gokcen Polat, Serhat Celik, Umit Yavuz Malkan, Guldane Cengiz Seval, Ali Dogan, Aydan Akdeniz, Demircan Ozbalci, Idris Ince, Ramazan Erdem, Ozgur Mehtap, Hakki Onur Kirkizlar, Murat Kacmaz, Burak Deveci, Fatma Aykas, Gulten Korkmaz, Sureyya Yigit Kaya, Hacer Berna Afacan Ozturk, Omur Gokmen Sevindik, Ferda Can, Demet Cekdemir, Ceyda Aslan, Hale Bulbul, Zeynep Tugba Karabulut, Senem Maral, Salih Sertac Durusoy, Fatih Demirkan, Hakan Goker, Fahir Ozkalemkas, Muzaffer Keklik, Selami Kocak Toprak, Aylin Fatma Karatas, Unal Atas and Inci Alacaciogluadd Show full author list remove Hide full author list
J. Clin. Med. 2025, 14(20), 7367; https://doi.org/10.3390/jcm14207367 - 18 Oct 2025
Viewed by 876
Abstract
Background: Acute myeloid leukemia (AML) is an aggressive and biologically diverse hematologic cancer that disproportionately affects older individuals. Despite advances in molecular profiling and therapy, long-term outcomes remain unsatisfactory. This nationwide registry was established to provide real-world insights into clinical characteristics, treatment [...] Read more.
Background: Acute myeloid leukemia (AML) is an aggressive and biologically diverse hematologic cancer that disproportionately affects older individuals. Despite advances in molecular profiling and therapy, long-term outcomes remain unsatisfactory. This nationwide registry was established to provide real-world insights into clinical characteristics, treatment strategies, and survival among adult AML patients in Turkey. Methods: The Turkish AML Registry Project (ClinicalTrials.gov Identifier: NCT05979675) combines retrospective and prospective data from 23 tertiary hematology centers. Adult patients diagnosed between January 2008 and July 2023 were included. Baseline demographics, European LeukemiaNet (ELN) 2017 risk groups, Eastern Cooperative Oncology Group (ECOG) performance status, treatment intensity, and targeted therapy use were analyzed. Response and survival outcomes were assessed using Kaplan–Meier methods. Results: The interim dataset included 891 patients (median age 58 years, 45.5% ≥60). Intensive chemotherapy, most commonly 7 + 3, was applied in 74.1%, while 25.9% received lower-intensity regimens. Targeted agents, mainly venetoclax, were incorporated more frequently into low-intensity therapies (19.1% vs. 3.4%, p < 0.001). Complete remission occurred in 70.2% after intensive and 35.9% after low-intensity therapy, improving to 51.4% with targeted agents. Median overall survival (OS) was 27.2 months, with 1-year OS rates of 54.1%, 28.9%, and 17.6% for favorable, intermediate, and adverse ELN groups (p < 0.001). ECOG 0–1 predicted superior survival (1-year OS 70.3% vs. 47.0%). Conclusions: Nationwide real-world evidence underscores the prognostic relevance of ELN risk and functional status in AML. While intensive chemotherapy remains central, combining targeted agents with low-intensity regimens improves outcomes in less fit patients and supports personalized treatment approaches. Full article
(This article belongs to the Special Issue Acute Myeloid Leukemia: Latest Advances in Diagnostics, Therapeutic Strategies and Clinical Management: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop